TRUMY:OTO-Terumo Corp. ADR (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 17.59

Change

+0.44 (+2.57)%

Market Cap

USD 12.77B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

+1.52 (+0.69%)

USD 104.77B
ESLOY Essilor International SA

+1.23 (+1.11%)

USD 104.51B
HOCPF HOYA Corporation

+2.30 (+1.87%)

USD 42.49B
HOCPY Hoya Corp

+1.61 (+1.35%)

USD 41.61B
RSMDF Resmed Inc DRC

N/A

USD 31.08B
CLPBY Coloplast A

+0.06 (+0.50%)

USD 27.81B
CLPBF Coloplast A/S

-1.47 (-1.21%)

USD 27.53B
TRUMF Terumo Corporation

+0.12 (+0.73%)

USD 25.47B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 21.79B
SAUHY Straumann Holding AG ADR

+0.10 (+0.77%)

USD 20.74B

ETFs Containing TRUMY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 115.70% 98% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.70% 95% A 95% A
Trailing 12 Months  
Capital Gain 139.97% 96% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 139.97% 93% A 95% A
Trailing 5 Years  
Capital Gain 152.28% 98% N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 152.28% 96% N/A 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 5.11% 46% F 49% F
Dividend Return 5.11% 41% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.31% 74% C 70% C-
Risk Adjusted Return 16.31% 49% F 51% F
Market Capitalization 12.77B 90% A- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector